Compare Merck & Co., Inc. (MRK) vs Impinj Inc (PI) Price & Performance

Merck & Co., Inc.Trade

Impinj IncTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Impinj Inc — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Impinj Inc trades at $137.09 (market cap $4.19B). The key difference: Merck & Co., Inc. is far larger — about 73.3× Impinj Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.

	MRK	PI
Market Cap	$307.25B	$4.19B
Sector	Health	Technology
52-Week High	$129.52	$241.91
52-Week Low	$77.60	$91.34
Enterprise Value	$350.66B	$4.33B
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

Impinj Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 7 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Impinj Inc

Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.